Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept

Transplantation. 2014 Feb 27;97(4):e30-2. doi: 10.1097/01.TP.0000441824.95510.97.

Authors

Jill C Krisl¹, Rita R Alloway, Adele Rike Shields, Michael A Cardi, E Steve Woodle

Affiliation

¹ 1 Work created as Transplant Pharmacy Fellow, Department of Surgery, Division of Transplantation, University of Cincinnati Academic Health Center, Cincinnati, OH 2 Transplant Clinical Research, University of Cincinnati Medical Center, Cincinnati, OH 3 Transplant Clinical Pharmacy, The Christ Hospital, Cincinnati, OH 4 Director of Kidney Transplantation, The Christ Hospital, Kidney and Hypertension Center, Cincinnati, OH 5 Director Division of Transplantation Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH.

PMID: 24531826
DOI: 10.1097/01.TP.0000441824.95510.97

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Abatacept
Adult
Azathioprine / adverse effects
Biopsy
Boronic Acids / administration & dosage*
Bortezomib
Calcineurin Inhibitors
Cyclosporine / adverse effects
Glomerulonephritis, IGA / therapy
Graft Rejection / prevention & control*
Humans
Immunoconjugates / administration & dosage*
Immunosuppression Therapy / methods
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Kidney Diseases / diagnosis
Kidney Failure, Chronic / therapy
Kidney Transplantation / methods*
Male
Prednisone / adverse effects
Pyrazines / administration & dosage*
Treatment Outcome

Substances

Boronic Acids
Calcineurin Inhibitors
Immunoconjugates
Immunosuppressive Agents
Pyrazines
Bortezomib
Abatacept
Cyclosporine
Azathioprine
Prednisone